These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36510639)

  • 21. Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas.
    Fukuya Y; Tamura M; Nitta M; Saito T; Tsuzuki S; Koriyama S; Kuwano A; Kawamata T; Muragaki Y
    J Neurooncol; 2023 Feb; 161(3):555-562. PubMed ID: 36749444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
    Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
    Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could Fluorescein Staining in Low-Grade Glial Tumors Guide for Peroperative Differentiation of Pathological Types?
    Ozden M; Mammadkhanli O; Zaimoglu M; Bayatli E; Bozkurt M
    Turk Neurosurg; 2023; 33(5):847-854. PubMed ID: 37309632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
    Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
    Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
    Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synchronous contralateral low-grade oligodendroglioma and high-grade IDH-mutant astrocytoma.
    White B; Filo J; Orrego-Gonzalez E; Schwartz SN; Varma H; Uhlmann EJ; Vega RA
    J Neuropathol Exp Neurol; 2023 Nov; 82(12):1048-1050. PubMed ID: 37875098
    [No Abstract]   [Full Text] [Related]  

  • 29. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
    Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
    Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma.
    Nadeem M; Shahzad UB; Tahir N; Areej A
    Neurosurg Rev; 2024 Aug; 47(1):512. PubMed ID: 39212803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH-1 polymorphisms in pilocytic astrocytomas.
    Prayson RA
    Ann Diagn Pathol; 2019 Dec; 43():151411. PubMed ID: 31677487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
    Santosh V; Rao S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.
    Liu Y; Chen H; Li G; Zhang J; Yao K; Wu C; Li S; Qiu X
    Cancer Biol Med; 2022 Nov; 19(10):1477-86. PubMed ID: 36350001
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
    Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
    Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
    Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
    Jo J; van den Bent MJ; Nabors B; Wen PY; Schiff D
    Neuro Oncol; 2022 Jul; 24(7):1035-1047. PubMed ID: 35137214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.